SARS-CoV-2 correlates of protection from infection against variants of concern
- PMID: 39060660
- PMCID: PMC11533127
- DOI: 10.1038/s41591-024-03131-2
SARS-CoV-2 correlates of protection from infection against variants of concern
Abstract
Serum neutralizing antibodies (nAbs) induced by vaccination have been linked to protection against symptomatic and severe coronavirus disease 2019. However, much less is known about the efficacy of nAbs in preventing the acquisition of infection, especially in the context of natural immunity and against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune-escape variants. Here we conducted mediation analysis to assess serum nAbs induced by prior SARS-CoV-2 infections as potential correlates of protection against Delta and Omicron infections, in rural and urban household cohorts in South Africa. We find that, in the Delta wave, D614G nAbs mediate 37% (95% confidence interval: 34-40%) of the total protection against infection conferred by prior exposure to SARS-CoV-2, and that protection decreases with waning immunity. In contrast, Omicron BA.1 nAbs mediate 11% (95% confidence interval: 9-12%) of the total protection against Omicron BA.1 or BA.2 infections, due to Omicron's neutralization escape. These findings underscore that correlates of protection mediated through nAbs are variant specific, and that boosting of nAbs against circulating variants might restore or confer immune protection lost due to nAb waning and/or immune escape. However, the majority of immune protection against SARS-CoV-2 conferred by natural infection cannot be fully explained by serum nAbs alone. Measuring these and other immune markers including T cell responses, both in the serum and in other compartments such as the nasal mucosa, may be required to comprehensively understand and predict immune protection against SARS-CoV-2.
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
Competing interests
C.C. has received grant support from Sanofi Pasteur, the US Centers for Disease Control and Prevention, the Bill & Melinda Gates Foundation, the Taskforce for Global Health, the Wellcome Trust and the South African Medical Research Council. A.v.G. has received grant support from Sanofi Pasteur, Pfizer related to pneumococcal vaccine, the US Centers for Disease Control and Prevention and the Bill & Melinda Gates Foundation. N.W. reports grants from Sanofi Pasteur and the Bill & Melinda Gates Foundation. N.A.M. has received an institutional grant from Pfizer to conduct research in patients with pneumonia and from Roche to collect specimens to assess a novel tuberculosis assay. J.M. has received grant support from Sanofi Pasteur. The other authors declare no competing interests.
References
-
- World Health Organization. Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meet... (2023).
-
- World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/ (accessed 20 June 2024).
-
- World Health Organization. WHO COVID19 Vaccine Tracker. https://covid19.trackvaccines.org/agency/who/ (accessed 20 June 2024).
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources